An observational study in COVID-19 and Dysfunctional Breathing, sponsored by Hôpital du Valais. Status unknown at 1 site in Switzerland. Open to participants aged 14 Years and older. Per ClinicalTrials.gov, last updated 2022-02-01.
Sponsored by Hôpital du Valais · Observational
Among 97 studies in COVID-19 with a site in Switzerland — 6 open to participants now, 10 under way, 1 of them phase 3. COVID-19 · Switzerland.
Among the 97 studies in COVID-19 with a site in Switzerland, this one is the 40th largest by planned enrollment of the 47 observational ones that give a count, is one of 25 that started in 2021, is one of 47 observational ones, and was the 75th registered.
7,990 studies on the registry are indexed under COVID-19; 466 are open to participants now.
Browse COVID-19 studies →6 of the 97 studies in COVID-19 with a site in Switzerland are open now. Recruiting first, the newest first:
Flurin Cathomas · Sites in Switzerland
Ages 18–65
Universitaire Ziekenhuizen KU Leuven · Sites in Switzerland, Belgium, Germany
Ages 18–70
Insel Gruppe AG, University Hospital Bern · Sites in Switzerland
Ages 18–120
Calmy Alexandra · Sites in Switzerland
Ages 16+
University Hospital, Basel, Switzerland · Sites in Switzerland
Ages 18+
A study can be open while its sites in Switzerland have not opened yet or have stopped. Only those recruiting at a site in Switzerland →
Of the 356 COVID-19 studies recruiting now, 207 (58%) set no upper age limit and 83 (23%) stop at 75 or younger; 91 take children under 18; 136 take healthy volunteers.
This study: 14 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
97 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 9 · Phase 3 21 · Phase 4 2
First in 2016; this study’s year is marked. 25 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 50 is below the median of 268 across 3,208 observational studies indexed under COVID-19.
Median enrollment 100 across the 49 interventional studies, 425 across the 47 observational. Of the 70 that completed or were terminated, 11 (16%) have results posted.
This tab as a report to print or save as PDF → With an account.
8 of 97 have an industry lead sponsor. The 10 most frequent:
Hôpital du Valais is the lead sponsor of 15 studies on the registry; 3 are open to participants now.
Hôpital du Valais has 1 study filed under COVID-19 — fewer than ten, so there is no comparison to draw.
2 of the studies in COVID-19 with a site in Switzerland that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06482138Universitaire Ziekenhuizen KU LeuvenDysfunction of Olfaction After COVID-19 Infection: Morphological and Histomolecular Investigation | 2026-12-31 |
| NCT06716996Flurin CathomasRTMS for the Treatment of Post-COVID Associated Affective Symptoms | 2027-10-31 |
Among the 97 studies in COVID-19 with a site in Switzerland, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Dysfunctional breathing might participate to dyspnoea in long COVID-19. This study investigate the prognosis of patients diagnosed with dysfunctional breathing after SARS-CoV-2 infection in our center.
Dysfunctional breathing (DB) with or without hyperventilation syndrome (HVS) as diagnosed using cardiopulmonary exercise test (CPET) was recently demonstrated as an important physiopathological mechanism of persistent dyspnoea in long COVID patients [1]. DB is characterized by specific ventilation pattern on CPET accompanied by respiratory discomfort and/or dyspnea at exercise [2]. Most patients with DB will have undergone some sort a specific physiotherapy retraining [3]. However the prognostic and the predictors of persistence/resolution of DB after severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection are unknown.
The aim of the study is to determine the prognostic of patients diagnosed with DB after SARS-CoV-2 infection, as well as prognosis factors and predictors of persistence/resolution of DB during a prospective follow up visit.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Persistence/resolution of dysfunctional breathing at follow-up visit
defined by persistence/resolution of dyspnea, as compared with patient's baseline (equivalent level of dyspnea as before COVID-19).
Time frame: 6 to 9 monts from diagnosis
Change in ventilatory patterns (tidal volume [VT], breathing frequency [BF] at isowork as compared with baseline
Time frame: 6 to 9 monts from diagnosis
Dispersion of VT and BF during the CPET
Time frame: 6 to 9 monts from diagnosis
Change in ETCO2 and PaCO2
Time frame: 6 to 9 monts from diagnosis
Qualitative changes (increase/decrease/no change of DB pattern of CPET)
Time frame: 6 to 9 monts from diagnosis
Score HADS changes
Time frame: 6 to 9 monts from diagnosis
Score SF-36 changes
Time frame: 6 to 9 monts from diagnosis
Specific symptom scale changes
Time frame: 6 to 9 monts from diagnosis
Specific work capacity changes questions
Time frame: 6 to 9 monts from diagnosis
Post-COVID Functional Status (PCFS) changes
Time frame: 6 to 9 monts from diagnosis
Plan to share: Undecided — Data upon reasonable requests
No publications or documents are linked to this record.
Started Nov 2021 (actual). Primary completion is estimated for Jun 2022, 7 months after the start.
Of 1,640 non-industry observational studies under COVID-19, half reached primary completion within 14 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 30. This study's planned 7 months is below that.
Counting every sponsor, half of 1,774 studies reached it within 13 months; a quarter within 5 and three quarters within 29.
How these figures are worked out, and which studies are left out of them.
This study is status unknown, as verified in Dec 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Hôpital du Valais